Skip to main content
Global Bioenergies logo

Global Bioenergies — Investor Relations & Filings

Ticker · ALGBE ISIN · FR0011052257 LEI · 969500H46XRAMTMVB676 PA Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2014-07-03 Regulatory Filings
Country FR France
Listing PA ALGBE

About Global Bioenergies

https://www.global-bioenergies.com/?lan…

Global Bioenergies develops and commercializes a process to convert renewable resources, such as plant-based sugars and agricultural waste, into isobutene. The company's proprietary technology utilizes fermentation and synthetic biology to produce this key hydrocarbon, which serves as a platform molecule for various applications. The bio-isobutene can be converted into ingredients for the cosmetics industry, specialty chemicals, and renewable fuels. A primary strategic focus is the production of Sustainable Aviation Fuel (SAF) to support the decarbonization of the aviation sector. The process provides a bio-based alternative to petroleum-derived hydrocarbons, aiming to reduce CO2 emissions and dependence on fossil fuels.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated July 3, 2014, announcing a contract signing between Global Bioenergies and Fraunhofer CBP regarding the commissioning and operation of an industrial pilot plant. It details a business development, partnership, and technical progress update, including funding support from a ministry. This type of announcement, focusing on strategic business operations, partnerships, and project milestones rather than routine financial results (ER/IR) or mandatory regulatory disclosures (10-K/DEF 14A), fits best under a general business update or regulatory filing category. Since it is not a formal financial report, a dividend notice, a management change, or a specific legal update, and it is a substantive announcement, it is classified as a general Regulatory Filing (RNS) as a catch-all for significant corporate news that doesn't fit the highly specific financial codes. The document length (4215 chars) is substantial enough that it is not merely an announcement of a report (RPA).
2014-07-03 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document announces a collaboration and contract signing between Global Bioenergies and Fraunhofer CBP regarding the commissioning and operation of an industrial pilot plant in Leuna. It details technical specifications, timelines (until September 2016), funding sources (BMBF), and future product applications (isobutene for plastics, fuels). This is a specific operational update concerning technology scaling and partnership, not a standard periodic financial report (like 10-K or IR), a formal earnings release (ER), or a management discussion (MDA). It is a significant business development announcement. Given the options, it best fits under 'Regulatory Filings' (RNS) as a general corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on the grant, but the core is a strategic operational agreement. Since it is a press release detailing a major operational milestone and partnership, and does not fit the specific financial report categories, RNS (Regulatory Filings) is the most appropriate fallback for a significant, non-standard announcement.
2014-07-03 French
Global Bioenergies and Fraunhofer CBP take the next step towards the set-up of the Leuna industrial pilot
Regulatory Filings Classification · 100% confidence The document is a short press release dated July 3, 2014, announcing that Global Bioenergies and Fraunhofer CBP have signed a contract for the commissioning and operation of an industrial pilot plant. It details a business development/alliance ('Contract/Alliance' keyword) regarding process up-scaling and facility setup. This type of announcement, focusing on strategic partnerships, contract signings, or operational milestones that are not standard financial reports (10-K, IR, ER), typically falls under general corporate news. Since it is not a specific filing like a Director's Dealing (DIRS), Capital Change (CAP), or Dividend (DIV), and it is not a full transcript (CT) or a formal regulatory filing like a major shareholding change (MRQ), the most appropriate category is the general Regulatory Filings (RNS) which serves as a catch-all for significant corporate news releases that don't fit other specific categories, especially given the 'DGAP' dissemination footer which implies a general regulatory news service.
2014-07-03 English
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 85% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Semi-annual balance sheet of the liquidity contract) and provides a status update on the liquidity contract as of June 30, 2014, comparing it to the December 31, 2013, balance. This is a periodic financial disclosure related to market making or liquidity provision, which is not explicitly covered by the main definitions like 10-K, IR, or ER. It details specific financial instruments (shares and cash) held under this contract. Since it is a specific, periodic financial update that doesn't fit the comprehensive report categories (10-K, IR) or specific announcements (DIV, CAP, etc.), it most closely aligns with a specialized financial disclosure. Given the options, it is a specific financial report/update. It is not a full Interim Report (IR) as it focuses only on the liquidity contract, not the entire company's operations or P&L. It is not an Earnings Release (ER) as it is not announcing core operational results. It is a specific financial status report. In the absence of a specific 'Liquidity Contract Update' code, and given that it is a detailed financial status update for a specific period (semi-annual), it is best classified as a specialized financial report. However, looking closely at the definitions, none perfectly capture a 'Liquidity Contract Balance Sheet'. It is a periodic financial statement update. If we must choose from the list, it is a specific financial disclosure. Since it is a periodic report detailing financial status (even if narrow in scope), and not just an announcement of a report (RPA), it should be classified as a report type. Given the options, and recognizing it as a periodic financial disclosure, it is closest to an Interim Report (IR) if we interpret 'Interim Report' broadly as any comprehensive report shorter than a year, although this document is very narrow. Alternatively, it could fall under Regulatory Filings (RNS) as a miscellaneous specific filing. Since it is a formal, periodic financial statement update (semi-annual), and not just a press release summary, I will lean towards the most relevant financial category. Since it is a 'Bilan Semestriel' (Semi-annual Balance Sheet), it functions like a component of an Interim Report. However, because it is highly specific and not a full financial statement, RNS (Regulatory Filings) is often the appropriate fallback for specialized, non-standard periodic disclosures. Given the highly specific nature and the lack of a better fit, RNS is the safest classification for a non-standard periodic financial disclosure.
2014-07-01 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document announces that Global Bioenergies is executing a first drawdown under an optional financing line signed with Yorkville Advisors. It details the issuance of 1,500 new shares at a specific price, which is a direct action related to raising capital or changing the capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and financing activities.
2014-06-10 French
Global Bioenergies secures a 3 million euro Equity Line
Share Issue/Capital Change Classification · 99% confidence The document is a corporate news release dated May 19, 2014, announcing that 'Global Bioenergies secures a 3 million euro Equity Line' via a Standby Equity Distribution Agreement (SEDA). This transaction involves a commitment for successive and limited capital increases, which directly relates to the company's capital structure and fundraising activities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV).
2014-05-19 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.